Studieoverzicht

Study name: DeLLphi-305

Histology	SCLC
Tumor stage	Stage IV
Host / recruiting sites	Erasmus MC, MUMC+
Enrollment	Planned
Therapy line	First line (1L)
Design	Randomized, open-label, multicenter, phase III
Intervention	Arm A: Tarlatamab and Durvalumab Arm B: Durvalumab
Key outcome parameters	To compare the efficacy amd safety of Tarlatamab and durvalumab with durvalumab alone on prolonging overall survival
Key inclusion criteria	Histologically or cytologically documented estensive-stage disease IV, SCLC or T3 to T4 due to multiple lung nodules that are too extensive of have tumor/nodal volume that is too large to be encompassed in a tolerable radiation plan. Completed 4 cycles of platinum-etoposide chemotherapy with concurrent durvalumab as first line treatment, without disease progression ECOG status of 0 or 1
Key exclusion criteria	Symptomatic central nervous system metastases, or leptomeningeal disease Systemic corticosteroid therapy of any other form of immunosuppresiive therapy within 14 days prior to first dose of study treatment
Contact information	Log in voor de contactinformatie